Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723428 | 1.00 | CHRM2 (0.56) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Hydrochloric Acid SCHEMBL597393 | 0.99 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Hydrochloric Acid SCHEMBL597394 | 0.99 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL27556305 | 0.93 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL27773494 | 0.93 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179164 | 0.93 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179157 | 0.93 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL1354913 | 0.91 | CHRM2 (0.53) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL1354912 | 0.91 | CHRM2 (0.53) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL2599542 | 0.90 | CHRM2 (0.47) | CHRM2CHRM1CHRM5CHRM3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | claimed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | claimed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | claimed |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-05-26 | — | — | US | claimed |
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-05-26 | — | — | US | disclosed |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-05-26 | — | — | US | disclosed |
| US-20110105783-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE | DIPHARMA FRANCIS S.R.I. (IT) | 2011-05-05 | — | — | US | disclosed |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ACTAVIS GROUP PTC EHF (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ACTAVIS GROUP PTC EHF (IS) | 2010-08-26 | — | — | US | disclosed |
| WO-2009037569-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF FESOTERODINE | ACTAVIS GROUP PTC EHF (IS) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037569-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF FESOTERODINE | ACTAVIS GROUP PTC EHF (IS) | 2009-03-26 | — | — | WO | disclosed |
| US-6858650-B1 | For therapy of urinary incontinence | SCHWARZ PHARMA AG (DE) | 2005-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105783-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE | HADHB, MAOB, FOSB | CHRM2 558/4885CHRM1 677/4885CHRM5 986/4885 |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | QDPR, FES, SULT1A1 | CHRM2 211/4885CHRM1 165/4885CHRM5 219/4885 |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ADRB3, FES, QDPR | CHRM2 107/4885CHRM1 279/4885CHRM5 111/4885 |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | FES, NISCH, RPS27A | CHRM2 530/4885CHRM1 646/4885CHRM5 1201/4885 |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | ADH1C, NISCH, ADH1A | CHRM2 10/4885CHRM1 11/4885CHRM5 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.